

From: dph.immunizations@ct.gov <noreply@everbridge.net>
Sent: Monday, October 16, 2023 2:32 PM
Subject: Limited Nirsevimab Supply



DEPARTMENT OF PUBLIC HEALTH

October 16, 2023

This communication is being sent to all key contacts at provider organizations enrolled in the CT Vaccine Program (CVP). Please feel free to share it with others in your organization who may benefit from the update. Note that all our communications are archived on our web site [here](#).

Dear CVP providers,

In light of high demand and limited supply of nirsevimab (trade name Beyfortus), the Centers for Disease Control and Prevention (CDC) is temporarily pausing public health ordering of this immunization. Private supply is equally constrained; see [link to a communication from Sanofi last week](#).

CDC has placed additional orders of nirsevimab with the manufacturer and plans to re-open ordering later this week with allocations in place. CDC anticipates additional doses of nirsevimab will be made available approximately every 2 to 3 weeks by the manufacturer. Currently, the 100mg nirsevimab vials are under tighter supply constraints than the 50mg vials.

Until further notice and for the duration while nirsevimab is on allocation, please place your nirsevimab orders using this [link](#). Other vaccines not on allocation should continue to be placed in CT WiZ as usual. Please assume your orders that were placed in CT WiZ last week will be filled with our upcoming allocation, and do not reorder those doses. It is likely that birth hospitals will be prioritized for our upcoming allocations, both because the 50mg vials can be maximized and because supply is expected to turnover faster in this setting.

We understand the challenges providers now face with the limited supply of nirsevimab. We are working with the CDC to advocate for as many doses as possible to come to Connecticut.

For the CT DPH Immunization Program, visit: [Contact Us](#)

If you would like to subscribe to receive these communications, please complete [this form](#). If you would like to unsubscribe from receiving these communications, please complete [this form](#).